Reading the tape
NASDAQ: LNTH
Lantheus Holdings, Inc.
Healthcare · Drug Manufacturers - Specialty & Generic
Market Cap
$5.59B
52w High
$108.91
52w Low
$47.25
P/E
24.10
Volume
729.03K
Outstanding Shares
65.10M
Price vs Fundamentals
Why The Stock Is Moving
Likely fundamental deteriorationModerate confidence
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
1Y Price: -20.39%Revenue (TTM): 0.5%FCF (TTM): -28.96%P/FCF: 47th pct
What changed
The stock fell 20.39% over the last year. Revenue grew 0.5% over the trailing twelve months. Operating margin moved from 29.38% to 20.16%. Free cash flow declined 28.96% over the trailing twelve months.
What the market seems to be pricing
The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/FCF, investors are still discounting lower future earnings power.
What would invalidate this read
Operating margin stands at 20.16%. Free cash flow fell 28.96% — a return toward positive territory would undermine the deterioration thesis. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Company profile
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.
CEOMary Anne Heino
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees808
IPO dateJun 25, 2015
Valuation
Forward P/E—
EV/EBITDA10.24
Enterprise value$4.13B
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Revenue growth4.01%
Gross margin61.1%▼5.16%vs FY2024
Operating margin20.16%▼32.32%vs FY2024
ROE21.43%▼25.37%vs FY2024
Analyst consensus
RatingBuy
Target price$101.00▲17.69%
13
Buy
4
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
May 7, 2026
Q2 FY26 · EPS est $1.25 · Revenue est $354.48M
View